Mode
Text Size
Log in / Sign up

Stroke prevalence 14% after LVAD, highest in Asia, projected to declineStroke rates for heart failure patients with LVAD devices vary by region

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Consider stroke risk when managing LVAD patients; prevalence is 14%, highest in Asia.

This meta-analysis pooled data from 132,869 patients receiving left ventricular assist device (LVAD) treatment across 16 countries to estimate the global and regional prevalence of stroke after LVAD implantation. The primary outcome was stroke prevalence, with secondary outcomes examining temporal and projected trends. The analysis did not report a comparator or follow-up duration.

The pooled global stroke prevalence was 14.0% (95% CI 12.0-15.0%). Regional differences were significant: Asia had the highest prevalence at 18.0% (p < 0.0001), while North America had the lowest at 12.0% (p < 0.0001). Between 2008 and 2024, stroke prevalence showed no significant change, indicating a stable trend. However, a smooth spline regression model projected a declining trend over the next decade (SE = 0.028).

The authors note that the projected decline is based on an exploratory model and should be interpreted with caution. Limitations were not reported in the source. No adverse events or safety data were reported.

These findings may help guide clinical practice, optimize patient management, and inform prevention strategies for stroke in LVAD recipients. However, given the observational nature of the pooled data and lack of reported limitations, clinicians should consider these estimates as context rather than definitive risk predictions.

How this fits prior evidence

This meta-analysis adds stroke-specific outcome data to prior heart failure coverage. It confirms that stroke remains a common complication after LVAD, with a global prevalence of 14.0%, complementing prior findings on device-based therapies like left bundle branch pacing. The regional variation (Asia 18.0% vs North America 12.0%) extends the evidence by highlighting geographic disparities. The stable temporal trend from 2008 to 2024 contrasts with the projected decline, which is exploratory. These results address a gap in quantifying stroke burden after LVAD, which was not covered in prior items.

Living with heart failure is a heavy burden, and many patients rely on a mechanical pump called a left ventricular assist device (LVAD) to keep their hearts pumping. While these devices are life-saving, patients still face the serious risk of stroke. New data from 16 countries helps us understand how these risks vary across the globe.

Researchers looked at over 132,000 patients and found that the global stroke rate for those with an LVAD is about 14 percent. However, the risk is not the same everywhere. Patients in Asia had the highest stroke rates at 18 percent, while those in North America had the lowest at 12 percent.

While stroke rates have remained stable since 2008, some models suggest a downward trend in the coming decade. These findings can help doctors better manage care and create better prevention plans for patients depending on where they live.

What this means for you:
Stroke rates for heart failure patients with LVAD devices are higher in Asia than in North America.

Common questions

How do stroke rates differ between regions for these patients?

Stroke rates vary significantly by location. Patients in Asia have the highest recorded rate at 18.0 percent. In contrast, patients in North America have the lowest recorded rate at 12.0 percent.

Are stroke rates for LVAD patients expected to change in the future?

While stroke rates have remained stable since 2008, some models suggest a declining trend for the next decade. However, these future projections are based on an exploratory model rather than confirmed trends.

Study Details

Study typeMeta analysis
Sample sizen = 132,869
EvidenceLevel 1
PublishedSep 2026
View Original Abstract ↓
INTRODUCTION: Stroke after left ventricular assist device (LVAD) implantation is a serious complication in patients receiving LVAD treatment. This study aims to estimate the global and regional prevalence, temporal trends, and projected trends of post-LVAD stroke. METHODS: This study compiled literature on stroke prevalence post-LVAD implantation through PubMed and Web of Science searches. Global and regional prevalence rates were aggregated. Sensitivity analyses, subgroup analyses, meta-regression analyses, and publication bias analyses were also conducted. A smooth spline regression model assessed temporal and projected trends. RESULTS: Data from 99 studies (132,869 patients) showed a 14.0% (95% CI 12.0-15.0%) stroke prevalence post-LVAD. The highest prevalence was observed in Asia at 18.0% ( < 0.0001), the lowest in North America at 12.0% ( < 0.0001). During the period from 2008 to 2024, the prevalence of stroke after LVAD implantation did not change significantly and remained at a relatively high level, and exploratory projections indicated a declining trend in the next decade (SE = 0.028). CONCLUSIONS: The global prevalence of stroke in LVAD patients is high (14%), but this is likely to decrease over the next decade. These findings can guide clinical practice, optimize patient management, and formulate prevention strategies. PROTOCOL REGISTRATION: www.crd.york.ac.uk/prospero identifier is CRD42024617821.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.